Short Bouts of Vigorous Physical Activity May Reduce Cancer Risk
Engaging in vigorous physical activity for 3 to 4 minutes per day is associated with a decrease in the risk of cancer among adults who typically don’t exercise, new research suggests.
Diagnosis & Disease Information
Outcomes of Unrelated, Haplo Transplant in AML Have Improved Over Time
In recent years, outcomes have improved for AML patients undergoing unrelated or haploidentical transplant in second complete remission.
Childhood Cancer Survivors Have Higher Risk of Late Surgical Interventions
Childhood cancer survivors have a higher risk of requiring surgical interventions up to 35 years after diagnosis, a large study suggests.
5 Factors That May Affect Multiple Myeloma Outcomes
What are some of the most important factors affecting outcomes in patients with multiple myeloma?
Delirium Tied to Increased Risk of Death in Critically Ill With Cancer
Critically ill patients with cancer who develop delirium have a higher risk of dying in the hospital or intensive care unit, a study suggests.
Iomab-B Enables ASCT in AML Patients Typically Not Eligible for Transplant
Iomab-B plus RIC enables ASCT in a population of AML patients who are not typically eligible for transplant, a phase 3 study suggests.
Adding Ibrutinib to Induction and Maintenance Improves FFS in Mantle Cell Lymphoma
Adding ibrutinib to induction and maintenance after transplant improves failure-free survival in patients with mantle cell lymphoma, results of the TRIANGLE study suggest.
Less May Be More When Treating Newly Diagnosed AML
Neither a higher dose of daunorubicin nor a second induction cycle improved outcomes in fit patients with newly diagnosed acute myeloid leukemia.
Diet Not Associated With Infection Risk in Patients With Neutropenia After HSCT
Randomized noninferiority study compared outcomes for patients with neutropenia after HSCT who followed a protective diet with those who followed a nonrestrictive diet.
Outcomes After BTK Inhibitor Failure in Rel/Ref Mantle Cell Lymphoma
A real-world study provides a benchmark for survival in MCL patients for whom BTK inhibitor treatment has failed, according to researchers.
- Loading...
Loading...
Next post in Lymphoma
Loading... 
Loading...